Trial Profile
An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib (Gleevec) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) With Persistent Molecular Disease.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 14 May 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 17 Dec 2012 Planned initiation date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 13 Jun 2012 Planned initiation date changed from 1 Feb 2011 to 1 Sep 2012 as reported by ClinicalTrials.gov.